Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Abeona Therapeutics Inc ABEO

Healthcare Biotechnology
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cell and gene therapies for life-threatening diseases. The Company’s lead clinical program is for prademagene zamikeracel (pz-cel), its investigational autologous, COL7A1 gene-corrected epidermal sheets currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The... see more

Recent & Breaking News (NDAQ:ABEO)

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Business Wire November 4, 2019

INVESTOR ALERT - Abeona Therapeutics Inc. (ABEO) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: January 2, 2019

ACCESSWIRE IA November 4, 2019

ABEONA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against Abeona Therapeutics, Inc. and Encourages Investors to Contact the Firm

Business Wire November 1, 2019

Pomerantz Law Firm Announces the Filing of a Class Action against Abeona Therapeutics Inc. and Certain Officers - ABEO

GlobeNewswire November 1, 2019

Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress

Thomson Reuters ONE October 21, 2019

Abeona Therapeutics Announces Presentations at the 27th European Society of Gene and Cell Therapy (ESGCT) Congress

GlobeNewswire October 21, 2019

Abeona Therapeutics Announces Publication of Positive Long-Term Data from Phase 1/2a Clinical Trial Evaluating EB-101 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

GlobeNewswire October 15, 2019

Lifshitz & Miller LLP Announces Investigation of Abeona Therapeutics Inc., Aptinyx Inc., James River Group Holdings, Ltd., The Chemours Company, Overstock.com, Inc., Greenland Acquisition Corporation and Wanda Sports Group Limited

PR Newswire October 10, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

ACCESSWIRE IA October 1, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

ACCESSWIRE IA September 27, 2019

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Abeona Therapeutics Inc. (ABEO)

ACCESSWIRE IA September 24, 2019

SHAREHOLDER ALERT: Investigation of Abeona Therapeutics Announced by Holzer & Holzer, LLC

Business Wire September 24, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEO

GlobeNewswire September 23, 2019

Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa

GlobeNewswire September 23, 2019

Abeona Therapeutics Announces Strategic Review

GlobeNewswire September 3, 2019

Abeona Therapeutics Announces Strategic Review

Thomson Reuters ONE September 3, 2019

Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates

GlobeNewswire August 9, 2019

Abeona Therapeutics Reports Second Quarter 2019 Financial Results and Business Updates

Thomson Reuters ONE August 9, 2019

Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA

GlobeNewswire July 25, 2019

Abeona Therapeutics Announces Positive Interim Data from the ABO-102 Phase 1/2 Gene Therapy Clinical Trial in MPS IIIA

Thomson Reuters ONE July 25, 2019